Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared an article by Charalampos S. Floudas, et al. on LinkedIn:
“Immunotherapy for HPV-Associated Cancers.
A recent phase 1/2 clinical trial published in JAMA Oncology explores a novel combination immunotherapy for advanced HPV-associated cancers. The study evaluates the efficacy of PDS01ADC (IL-12 antibody-drug conjugate), bintrafusp alfa (PD-L1/TGF-β inhibitor), and PDS0101 (HPV-16 therapeutic vaccine) in previously treated patients.
Key findings:
- 36.7% response rate in immune checkpoint blockade–naive patients.
- 62.5% response rate in patients with HPV-16–positive tumors.
- Promising antitumor activity and improved survival.
These results highlight the potential of this combination therapy, warranting further investigation.
Could this be a new standard for HPV-associated cancers?”
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical Trial.
Authors: Charalampos S. Floudas, et al.
